These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

935 related items for PubMed ID: 25965706

  • 1. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY, Merino J, Ezekowitz M, Ellenbogen K, Zamoryakhin D, Lanz H, Jin J, Al-Saadi N, Mercuri M, Goette A.
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
    Lip GYH, Merino JL, Dan GA, Themistoclakis S, Ellenbogen KA, De Caterina R, Goudev A, Jin J, Melino M, Winters SM, Goette A.
    Am J Cardiol; 2018 Jan 15; 121(2):193-198. PubMed ID: 29169605
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GYH, Al-Saady N, Ezekowitz MD, Banach M, Goette A.
    Am Heart J; 2017 Nov 15; 193():16-22. PubMed ID: 29129251
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF).
    Lip GYH, Merino JL, Banach M, de Groot JR, Maier LS, Themistoclakis S, Boriani G, Jin J, Melino M, Winters SM, Goette A.
    Am J Cardiol; 2019 Feb 15; 123(4):592-597. PubMed ID: 30527775
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E.
    Am Heart J; 2010 Oct 15; 160(4):635-41. PubMed ID: 20934556
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial.
    Kozieł M, Merino JL, De Caterina R, Huber K, Jin J, Melino M, Goette A, Lip GYH, ENSURE-AF Investigators.
    Eur J Clin Invest; 2020 May 15; 50(5):e13221. PubMed ID: 32150758
    [Abstract] [Full Text] [Related]

  • 13. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E, ENGAGE AF-TIMI 48 Investigators.
    Circ Arrhythm Electrophysiol; 2017 Jan 15; 10(1):. PubMed ID: 28077507
    [Abstract] [Full Text] [Related]

  • 14. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
    Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E.
    Circulation; 2016 Jul 05; 134(1):24-36. PubMed ID: 27358434
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
    Giugliano RP, Ruff CT, Wiviott SD, Nordio F, Murphy SA, Kappelhof JA, Shi M, Mercuri MF, Antman EM, Braunwald E.
    Am J Med; 2016 Aug 05; 129(8):850-857.e2. PubMed ID: 26994510
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.